Genotype Correlations with Blood Pressure and Efficacy from a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Blood Pressure
  • Carcinoma, Renal Cell
  • Imidazoles
  • Indazoles
  • Kidney Neoplasms
  • Niacinamide
  • Phenylurea Compounds

abstract

  • No SNP predicted axitinib outcomes. Although VEGFR2 rs2071559 predicted sorafenib efficacy in patients with mRCC, sensitivity/specificity limitations preclude its use for selecting individual patients for sorafenib treatment.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.clgc.2015.02.007

PubMed ID

  • 25816720

Additional Document Info

start page

  • 328

end page

  • 337.e3

volume

  • 13

number

  • 4